Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new cancer drug, COM902, to see if it is safe and works well against cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have previously been treated with specific immune-targeting medications.I have received PARP inhibitor therapy.My condition is at stage IV.I am fully active or can carry out light work.I have been treated with a PVRIG inhibitor before.I have been treated with a TIGIT inhibitor before.My ovarian cancer came back less than 6 months after platinum treatment.My cancer is a type of colon/rectum cancer confirmed by lab tests.I have an advanced cancer and have tried all standard treatments or can't receive them.My condition worsened after 3 or fewer treatments including specific chemotherapy drugs.I have had 3 or fewer treatments for ovarian cancer, not counting maintenance drugs.I have lung inflammation or disease causing symptoms.My colorectal cancer is MSS as confirmed by an approved test.I stopped immunotherapy due to an immune-related side effect.I have advanced cancer in my ovary, fallopian tube, or the lining of my abdomen.
- Group 1: COM902 + COM701 combination cohort expansion both at RDFE.
- Group 2: COM902 monotherapy dose escalation.
- Group 3: MSS-CRC Triplet combination (COM902 + COM701 + Pembrolizumab).
- Group 4: Platinum resistant ovarian cancer Triplet combination (COM902 + COM701 + Pembrolizumab).
- Group 5: COM902 monotherapy cohort expansion at RDFE.
- Group 6: Dual combination (COM902 + COM701) for evaluation of safety/tolerability (both at RDFE).
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many healthcare institutions are overseeing this clinical trial?
"This research is currently enrolling participants from 6 sites, located in cities such as Dallas, Memphis and Grand Rapids. It's recommended to pick a site close to your residence; this way you can reduce the burden of travelling if accepted into the study."
How reliable is the COM902 monotherapy dose increase procedure for human health?
"Our internal analysis gives Dose escalation: COM902 monotherapy. a score of one, due to the limited research that has been conducted on its safety and therapeutic potency."
Are applications being accepted for this experimental research program?
"Per the clinicaltrials.gov website, enrollment for this medical trial is still active after its initial posting on March 31st of 2020 and subsequent update from August 8th 2022."
What is the ceiling for enrollees in this clinical study?
"This trial necessitates 90 individuals that fit the specified criteria to join. Patients may go to Mary Crowley Cancer Research in Dallas, Tennessee or The University of Tennessee WEST Cancer Center in Memphis, Michigan for participation."
Share this study with friends
Copy Link
Messenger